N-glucuronides: on the rise?

We’ve observed an increase in synthesis requests for N-glucuronides over the last few years. We speculate that this may be due to the growing inclusion of nitrogen containing heterocycles in the design of new small molecule drugs, and pan company strategies to reduce CYP metabolism.

The situation is further complicated by the high interspecies variability in formation of some N-glucuronides, especially aliphatic tertiary amines and aromatic N-heterocycles. 

UGT1A4 and UGT2B10 are key enzymes responsible for N-glucuronidation reactions in humans, rates of which can be much higher than in other animals.

To compound this, synthesis of N-glucuronides isn’t always straightforward - read about Hypha's solutions to accessing and characterising N-glucuronides here.

More great client feedback

We've received some more feedback for the excellent work Hypha scientists did to ensure successful completion of a challenging metabolite project for a US pharma client. 

“Hypha Discovery was a huge help to our drug development timeline, when an ADME study revealed significant metabolites that were challenging to synthesize chemically. Hypha was able to rapidly reproduce the metabolites to confirm chemical structure, and then scale up to support nonclinical testing and bioanalytical method development, with far greater speed than chemical synthesis could achieve. The Hypha people were very pleasant to work with and the material they produced was of very high quality, which rounded out an overall great experience. I would recommend them without reservation.”

Senior VP Pharmaceutical Sciences, US Pharma company